Acute and chronic antiparkinsonian effects of the novel nociceptin/orphanin<scp>FQ</scp>receptor antagonist<scp>NiK</scp>‐21273 in comparison with<scp>SB</scp>‐612111
Matteo Marti(University of Ferrara), Michele Morari(University of Padua), Mirco Budri(University of Ferrara), Girolamo Calò(University of Padua), N T Zaveri(Astraea Therapeutics (United States)), Stefano Molinari(University of Ferrara), F Mela(University of Ferrara), Davide Malfacini(University of Bonn), Paola Petrillo(Tecnologie Avanzate (Italy)), Silvio Ronzoni(Tecnologie Avanzate (Italy)), Mattia Volta(Eurac Research)
Cited by 28
Related Papers
THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors
|British Journal of Pharmacology|2021|488
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
|Progress in Neurobiology|2015|472
Pharmacology of nociceptin and its receptor: a novel therapeutic target
|British Journal of Pharmacology|2000|432
The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors
|British Journal of Pharmacology|2023|390